A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

Group 1 ELND005

DRUG

Group 2 ELND005

Trial Locations (46)

14620

TransitionTIL Investigational Site, Rochester

14623

TransitionTIL Investigational Site, Rochester

15213

TransitionTIL Investigational Site, Pittsburgh

19001

TransitionTIL Investigational Site, Abington

19046

TransitionTIL Investigational Site, Jenkintown

19401

TransitionTIL Investigational Site, Norristown

20057

TransitionTIL Investigational Site, Washington D.C.

21601

TransitionTIL Investigational Site, Easton

27103

TransitionTIL Investigational Site, Winston-Salem

27710

TransitionTIL Investigational Site, Durham

28040

TransitionTIL Investigational Site, Madrid

28211

TransitionTIL Investigational Site, Charlotte

28401

TransitionTIL Investigational Site, Wilmington

29935

TransitionTIL Investigational Site, Port Royal

31419

TransitionTIL Investigational Site, Savannah

31909

TransitionTIL Investigational Site, Columbus

32806

TransitionTIL Investigational Site, Orlando

33064

TransitionTIL Investigational Site, Deerfield Beach

33334

TransitionTIL Investigational Site, Oakland Park

33445

TransitionTIL Investigational Site, Delray Beach

33449

TransitionTIL Investigational Site, Lake Worth

33462

TransitionTIL Investigational Site, Atlantis

33952

TransitionTIL Investigational Site, Port Charlotte

34243

TransitionTIL Investigational Site, Sarasota

35294

TransitionTIL Investigational Site, Birmingham

55130

TransitionTIL Investigational Site, Saint Paul

62702

TransitionTIL Investigational Site, Springfield

73112

TransitionTIL Investigational Site, Oklahoma City

75115

TransitionTIL Investigational Site, DeSoto

85004

TransitionTIL Investigational Site, Phoenix

85006

TransitionTIL Investigational Site, Phoenix

90806

TransitionTIL Investigational Site, Long Beach

91316

TransitionTIL Investigational Site, Encino

92025

TransitionTIL Investigational Site, Escondido

92658

TransitionTIL Investigational Site, Newport Beach

92868

TransitionTIL Investigational Site, Orange

93710

TransitionTIL Investigational Site, Fresno

98007

TransitionTIL Investigational Site, Bellevue

06851

TransitionTIL Investigational Site, Norwalk

01890

TransitionTIL Investigational Site, Winchester

97225-6625

TransitionTIL Investigational Site, Portland

M6M 3Z5

TransitionTIL Investigational Site, Toronto

03203

TransitionTIL Investigational Site, Elche

08221

TransitionTIL Investigational Site, Terrassa

08028

TransitionTIL Investigational Site, Barcelona

SN3 6BW

TransitionTIL Investigational Site, Swindon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

OPKO Health, Inc.

INDUSTRY